Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
DMIIR0.140USD
0.000
Market hours （ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 Company
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 Info
Ticker SymbolDMIIR
Company nameDrugs Made In America Acquisition II Corp
IPO dateSep 25, 2025
CEOStockwell (Lynn)
Number of employees- -
Security typeRight
Fiscal year-end- -
Address1 East Broward Boulevard
CityFT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone19548703099
Website
Ticker SymbolDMIIR
IPO dateSep 25, 2025
CEOStockwell (Lynn)
Company Executives of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
Name
Name/Position
Position
Shareholding
Change
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030?
The top five shareholders of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 are:
What are the top three shareholder types of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030?
The top three shareholder types of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 are:
Other
Other
How many institutions hold shares of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 (DMIIR)?
As of --, -- institutions hold shares of Drugs Made In America Acquisition II Rights Exp 16 Sep 2030, with a combined market value of approximately --, accounting for --% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for Drugs Made In America Acquisition II Rights Exp 16 Sep 2030?
In --, the -- business generated the highest revenue for Drugs Made In America Acquisition II Rights Exp 16 Sep 2030, amounting to -- and accounting for --% of total revenue.
